Inhibikase Therapeutics replaces auditor CohnReznick with Deloitte

• Inhibikase Therapeutics replaced auditor CohnReznick with Deloitte as independent accountant for fiscal 2026, effective Aug. 21, 2026.
• CohnReznick’s audit opinions for 2025 and 2024 were clean, with no adverse opinion, disclaimer, or scope or accounting qualifications.
• No accounting or auditing disagreements were reported with CohnReznick through its dismissal date.
• A previously disclosed material weakness in internal controls was flagged in 2024, then remediated by prior management in 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibikase Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-368296), on August 26, 2026, and is solely responsible for the information contained therein.